부데소니드 흡입기 시장 : 제품 종류별, 제형별, 유효 성분 농도별, 유통 채널별, 지역별

Budesonide Inhaler Market is estimated to be valued at USD 8,709 Mn in 2026 and is expected to reach USD 13,099 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6% from 2026 to 2033.

Budesonide is an artificial glucocorticoid steroid related to the naturally-occurring hormone, cortisol or hydrocortisone, which is produced in the adrenal glands. It is used for treating asthma. Budesonide is sold under the brand name Pulmicort. Each budesonide inhaler is designed to provide 60 to 120 inhalations depending on the device. Increasing air population is expected to lead to high prevalence of asthma worldwide. For instance, on May 11, 2022, according to the World Health Organization (WHO), Asthma is a major non-communicable disease (NCD), affecting both children and adults, and is the most common chronic disease among children globally. Asthma affected an estimated 262 million people in 2019 and caused 455 000 deaths globally. Most asthma-related deaths occur in low- and lower-middle-income countries such as India and Bangladesh, where under-diagnosis and under-treatment is a challenge.

Market Dynamics

The global demand for budesonide inhaler is expected to witness substantial growth over the forecast period, owing to increasing incidences and prevalence of asthma. According to the Global Asthma Report 2018, asthma causes around 1,000 deaths every day and affects as many as 339 million people worldwide.

Increasing product launch by the key market player in expected to boost the growth of global budesonide inhaler market over the forecast period. For instance, in November 2019, Lupin, Pharmaceutical Company, announced the launch of device to track usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases. The device helped the patients track their metered-dose inhalers (MDI) usage and facilitate improved adherence to therapy. The inhalers are the treatment option for managing chronic respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD).

Key features of the study

• This report provides an in-depth analysis of the global budesonide inhaler market, market size (USD Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 - 2030, considering 2021 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global budesonide inhaler market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include, Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global budesonide inhaler market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global budesonide inhaler market.

Budesonide Inhaler Market Segmentation

• By Product Type Insights (Revenue, USD Mn, 2020 - 2033)
  • Inhalants
  • Nebulizer
• By Dosage Form Insights (Revenue, USD Mn, 2020 - 2033)
  • Aerosols
  • Dry Powder
  • Suspension
  • Sprays
• By Strength Insights (Revenue, USD Mn, 2020 - 2033)
  • 0.25mg
  • 0.5mg
  • 1.0mg
• By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region Insights (Revenue, USD Mn, 2020 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players
  • Pfizer Inc.
  • Cipla Limited
  • Lupin Limited
  • Cosmo Pharmaceuticals
  • Takeda Pharmaceutical Company Ltd.
  • Manus Aktteva Biopharma LLP
  • Abbott Laboratories
  • Lunan Better Pharmaceutical
  • Novartis International AG (Sandoz)
  • Mylan N.V.
  • Skyepharma
  • AstraZeneca Plc.
  • Chiesi Farmaceutici S.p.A
  • Orion Corporation
  • Santarus Inc.
  • Synmosa Biopharma Corporation
  • Shanghai Sine Pharmaceutical Laboratories Co. Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
• Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Dosage Form
  • Market Snapshot, By Strength
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Landscape
• Product Recall
• Epidemiology Analysis
• Technology Overview
• PEST Analysis
• Porter's Five Forces Model

4. Global Budesonide Inhaler Market, By Product Type, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Inhalants
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Nebulizers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

5. Global Budesonide Inhaler Market, By Dosage Form, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Aerosols
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Dry Powder
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Suspension
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Spray
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

6. Global Budesonide Inhaler Market, By Strength, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• 25mg
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• 5mg
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• 0mg
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

7. Global Budesonide Inhaler Market, By Distribution Channel, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

8. Global Budesonide Inhaler Market, By Region, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026 - 2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • UK
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Heat Map Analysis
• Company Profile
  • Pfizer, Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Cipla Limited
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Lupin Limited
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Cosmo Pharmaceuticals
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Takeda Pharmaceutical Company Ltd
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Manus Aktteva Biopharma LLP
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Abbott Laboratories
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Lunan Better Pharmaceutical
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Novartis International AG (Sandoz)
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Mylan N.V.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Skyepharma
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • AstraZeneca Plc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Chiesi Farmaceutici S.p.A.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Orion Corporation
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Santarus Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Synmosa Biopharma Corporation
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
• Analyst Views

10. Section

• References
• Research Methodology
• About Us